Table 1.

Main results of studies assessing the effect of anti-TNF treatment on bone mineral density in patients with rheumatoid arthritis

Author	Year	Drug	Patients (n)	Controls (n)	Follow-up (months)	Femoral BMD		Lumbar BMD		Hand BMD
						Pts	Ctr	Pts	Ctr	Pts	Ctr
Lange	2005	INF	26	–	12	↑	–	↑	–	–	–
Vis	2005	INF	36	–	12	↓ (NS)	–	↑ (NS)	–	–	–
Seriolo	2006	INF/ETA	9/11	10	6	↑ (NS)	↓ (NS)	↑ (NS)	↓ (NS)	(↑)	(↓)
Vis	2006	INF	102	–	12	↔	–	↔	–	↓	–
Marotte	2007	INF	90	99	12	↔	↓	↔	↓	–	–
Chopin	2008	INF	48	–	12	↔	–	↔	–	–	–
Guler-Yuksel	2008	INF	88	254	12	↓ (NS)	↓ (NS)	↓ (NS)	↓ (NS)	–	–
Haugeberg	2009	INF	10	10	12	↔	↓	↓	↓	↓	↓
Hoff	2009	ADA	261+261	246	24	–	–	–	–	↓	↓
Wijbrandts	2009	ADA	50	–	12	↔	–	↔	–	–	–
Eekman	2011	INF	52	–	24	↔	–	↑	–	↓	–
Hoff	2011	ADA	214	188	12	–	–	–	–	↓	↓
Bertoldi	2013	ETA	5	7	12	–	–	–	–	↑	↑
Dischereit	2013	INF	18	–	24	↔	–	↓	–	–	–
Krieckaert	2013	ADA	184	–	48	↓	–	↔	–	↓	–
Szentpetery	2013	ETA/ADA/INF	35	–	36	↓	–	↔	–	↔	–
Okano	2014	INF/ETA	90/27	102	12	↔	↓	↔	↔	–	–

ADA, Adalimumab; BMD, bone mineral density; Ctr, controls; ETA, etanercept; INF, infliximab; NS, not significant; Pts, patients.